Azad, Arun A

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., et al. (2023) · The Lancet

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 538

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., et al. (2024) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 230

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 167

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

Annala, M., Fu, S., Bacon, J. V. W., Sipola, J., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S. J., Lo, G., et al. (2021) · Annals of Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 73

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies

Iravani, A., Violet, J., Azad, A., & Hofman, M. S. (2020) · Prostate Cancer and Prostatic Diseases

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

Cited by 68

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

Fizazi, K., Azad, A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 17

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer

Scheinberg, T., Lin, H.-M., Fitzpatrick, M., Azad, A. A., Bonnitcha, P., Davies, A., Heller, G., Huynh, K., Mak, B., Mahon, K., et al. (2024) · Prostate Cancer and Prostatic Diseases

Cancer, Lipids, and MetabolismProstate Cancer Treatment and Research

Cited by 15